Mayo specialist for Cytopia
Wednesday, 30 July, 2008
Cytopia [ASX: CYT] has appointed a study chair for Phase I clinical trials of its new JAK2 enzyme inhibitor.
Dr Ayalew Tefferi is professor of medicine in haematology at the Mayo Clinic College of Medicine in the US.
JAK2 is a mutant enzyme which occurs in myelofibrosis patients, a disorder which causes bone marrow to be replaced by fibrous scar tissue. JAK2 can also cause other blood disorders, many of which can lead to conditions such as leukemia.
Cytopia expects to be ready to file an Investigational New Drug application for the treatment with the US FDA by the end of the year.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
